Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactiplantibacillus plantarum HD02
- Development stage
- Preclinical
- Lead developer
- GI Biome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactiplantibacillus plantarum HD02 is a probiotic bacterial strain originally isolated from the fermented food kimchi. It is being developed by HEM Pharma as a live biotherapeutic for the prevention and treatment of allergic diseases, specifically atopic dermatitis (eczema). The strain's mechanism of action involves the inhibition of mast cell degranulation, which leads to a reduction in the release of inflammatory mediators and decreased vascular permeability. In preclinical murine models of atopic dermatitis induced by MC903 or house dust mites, L. plantarum HD02 demonstrated the ability to lower blood levels of mast cell protease-1 (MCPT-1) and total IgE, while increasing the population of splenic Foxp3+ regulatory T cells and reducing immune cell infiltration in draining lymph nodes. The strain exhibits therapeutic efficacy through both the live bacteria and its secreted metabolites in cell-free culture supernatant.
- Other names
- L. plantarum HD02Lactiplantibacillus plantarum HD02
02
Targets
FOXP3 (Forkhead box protein P3)CMA1 (Chymase)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on lactiplantibacillus plantarum HD02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactiplantibacillus plantarum HD02.